CRISPR Gene Editing Technique Featured in Upcoming Myeloma Immunotherapy Trial
A Phase 1 clinical trial that uses the gene editing tool CRISPR to engineer multiple myeloma cellular immunotherapy will soon be underway at the…
Magdalena Kegel, — 
Articles by Magdalena Kegel
First Patient Dosed in Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma
The first patient has been dosed in a Phase 1 trial of P-BCMA-101, a new, more powerful type of CAR T-cell therapy to fight multiple…
Multiple Myeloma Patients Remain On Treatment Far Less than in Clinical Trials, Study Finds
Patients with relapsed or refractory multiple myeloma who are treated with new therapy combinations remain on their treatments far shorter than those participating in clinical…
Empliciti Improves Response to Combo Treatment in Newly Diagnosed Myeloma Patients, Study Finds
Newly diagnosed multiple myeloma patients respond better to treatment when Empliciti (elotuzumab) is added to a combination of Revlimid (lenalidomide) and dexamethasone,…
BioLineRx Readies Phase 3 Myeloma Trial to Mobilize Stem Cells for Transplant
BioLineRx has launched a Phase 3 trial to assess if adding BL-8040 to standard treatment will improve the outflux of blood stem cells from…
Weighing Myeloma Cells Could Predict Treatment Responses, MIT Study Shows
Weighing individual cancer cells could help doctors predict how multiple myeloma patients will respond to treatments, a Massachusetts Institute of Technology study reports. The findings could…
First Myeloma CAR T-cell Therapy Phase 2 Trial Opens Enrollment
The U.S. Food and Drug Administration (FDA) has granted Celgene and Bluebird Bio’s bb2121 — the first CAR T-cell therapy for multiple myeloma —…
FDA Allows Trials of Opdivo Combo Therapy to Resume, Signaling No New Safety Concerns
The U.S. Food and Drug Administration (FDA) agreed to allow two clinical trials of Opdivo (nivolumab)-based combinations for myeloma to resume, after being put on partial…
Poseida Developing CAR T-cells to Replace Risky Stem Cell Transplant Pre-treatments
Poseida Therapeutics is developing CAR T-cell therapies that can get rid of cancer-generating bone marrow cells before a blood cancer patient receives a stem…
Janssen to Share Updates from Darzalex Studies at Hematology Meeting in Atlanta
Janssen plans to share new data from Phase 3 trials of Darzalex (daratumumab) for multiple myeloma at the 59th American Society of Hematology (ASH) Annual…